Cadrenal Therapeutics, Inc. (CVKD) AI Stock Analysis

• Market Cap: $16.25M
• Dividend Yield: N/A
• Average Volume (3M): 47.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: N/A
• EPS Growth: -9.80%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.31
• Shares Outstanding: 2,338,127
• 10 Day Avg. Volume: 41,807
• 30 Day Avg. Volume: 47,886
• PEG Ratio: 0.18
• Price to Book (P/B): 2.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.40
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.09K
• Enterprise Value/Ebitda: -0.86
• 1Y Price Target: $45.00
• Price Target Upside: 248.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -4.99
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $7.00 ▼(-45.82% Downside)

The score is primarily held down by weak financial performance (no revenue, widening losses, and significant cash burn with likely external funding needs). Technicals are mixed but still skew negative versus longer-term moving averages, and valuation metrics are limited by losses. Offsetting these risks, recent corporate events modestly improve the outlook by strengthening the pipeline and leadership.

Positive Factors

Pipeline expansion — VLX-1005 acquisition

Acquisition adds a first-in-class candidate targeting HIT and broadens the company beyond tecarfarin. Orphan/Fast Track status can accelerate development and commercial timeline, increasing strategic optionality and long-term addressable market exposure in anticoagulation.

Regulatory advantages for VLX-1005

Orphan and Fast Track designations provide potential regulatory acceleration, exclusivity benefits, and prioritized agency interactions. These structural advantages can reduce time-to-market and lower regulatory risk, enhancing value capture potential for a small clinical-stage company.

Very low financial leverage

Zero reported debt materially reduces fixed financing obligations and interest exposure, preserving cash flexibility to fund R&D or restructure programs. For a pre-revenue biotech, low leverage supports strategic optionality for partnerships or staged financing decisions over the medium term.

Negative Factors

Pre-revenue with widening net losses

Sustained, growing losses with no revenue base undermine self-funding capacity and increase dependency on external capital. Over 2–6 months this constrains the company’s ability to advance multiple clinical programs and elevates execution risk if additional financing is delayed or costly.

Accelerating negative operating and free cash flow

Deepening negative OCF/FCF signals rapid cash depletion and a narrow runway absent new funding. This structural cash-burn dynamic forces prioritization of programs, increases reliance on dilutive financings or partnerships, and can slow clinical timelines or reduce bargaining power.

Shrinking assets/equity, elevating dilution risk

Material declines in assets and shareholders' equity weaken the balance-sheet cushion and raise the likelihood of recurring capital raises. Combined with persistent cash burn, this heightens structurally-driven dilution risk and could constrain long-term program funding without strategic partnerships.

Cadrenal Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

How the Company Makes Money

Cadrenal Therapeutics makes money primarily through the development and commercialization of proprietary pharmaceuticals. Revenue is generated from the sale of these drugs once they receive regulatory approval and are brought to market. Additionally, the company may engage in strategic partnerships and collaborations with other pharmaceutical firms, which can provide additional revenue streams through licensing agreements, milestone payments, and royalties. These partnerships can also help Cadrenal Therapeutics expand its market reach and accelerate the development of its product pipeline.

Cadrenal Therapeutics, Inc. Financial Statement Overview

Summary

Pre-revenue with widening net losses (TTM net loss about -$14.4M) and accelerating operating/free-cash-flow burn (TTM OCF/FCF about -$11.8M). Balance sheet leverage is low (debt $0), but assets and equity have declined notably, increasing financing/dilution risk.

Income Statement

CVKD is still pre-revenue (revenue is $0 across all periods provided), so losses are driven by operating spend rather than business scale. Losses have widened meaningfully over time, with net loss deteriorating from about -$6.7M (2022) to -$8.4M (2023) to -$10.7M (2024) and -$14.4M in TTM (Trailing-Twelve-Months). With no revenue base, reported profit margins are not informative, and near-term earnings visibility remains weak.

Balance Sheet

The balance sheet shows very low leverage: total debt is $0 in 2024 and TTM (Trailing-Twelve-Months), and was minimal in 2023. Equity is positive in 2023–TTM (Trailing-Twelve-Months), but it has declined sharply from ~$7.4M (2024) to ~$2.7M (TTM), consistent with ongoing losses and cash burn. Total assets also fell from ~$10.1M (2024) to ~$4.1M (TTM), indicating reduced balance-sheet resources; while leverage risk is low, dilution/financing risk is elevated if losses continue.

Cash Flow

Cash generation is weak with persistent cash burn: operating cash flow is negative in every period and worsened from about -$1.2M (2022) to -$3.5M (2023) to -$7.4M (2024) and -$11.8M in TTM (Trailing-Twelve-Months). Free cash flow closely tracks operating cash flow and is deeply negative (about -$11.8M TTM), signaling a continued need for external funding. While free cash flow growth is positive in TTM (Trailing-Twelve-Months), it remains negative in absolute terms, so liquidity runway is the key watch item.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	-5.92K	-1.88K	0.00	-1.27K
EBITDA	-14.45M	-10.65M	-8.34M	-6.61M
Net Income	-14.39M	-10.65M	-8.36M	-6.71M
Balance Sheet
Total Assets	4.09M	10.12M	8.52M	778.17K
Cash, Cash Equivalents and Short-Term Investments	3.86M	10.02M	8.40M	32.59K
Total Debt	0.00	0.00	21.35K	640.71K
Total Liabilities	1.35M	2.68M	826.88K	6.33M
Stockholders Equity	2.73M	7.44M	7.69M	-5.55M
Cash Flow
Free Cash Flow	-11.83M	-7.36M	-3.53M	-1.20M
Operating Cash Flow	-11.82M	-7.36M	-3.53M	-1.20M
Investing Cash Flow	-11.64K	-6.54K	-3.25K	-2.28K
Financing Cash Flow	11.33M	8.98M	11.90M	1.24M

Cadrenal Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Negative. The current price of 12.92 is above the 20-day moving average (MA) of 7.68, above the 50-day MA of 8.60, and above the 200-day MA of 12.16, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 39.81 is Neutral, neither overbought nor oversold. The STOCH value of 33.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVKD.

Cadrenal Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLGN	48 Neutral	$24.03M	-1.85	-92.74%	―	280.77%	32.82%
CVKD	47 Neutral	$16.25M	-0.87	-468.03%	―	―	-9.80%
DARE	47 Neutral	$25.86M	-4.10	―	―	―	―
HIND	46 Neutral	$10.84M	-0.01	-565.18%	―	-48.74%	89.18%

Cadrenal Therapeutics, Inc. Corporate Events

Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity

On December 23, 2025, Cadrenal Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to continue using its at-the-market equity offering program, allowing the company to offer and sell up to an additional $1,770,028 of its common stock through H.C. Wainwright & Co. as sales agent. This supplemental capacity, which follows approximately $10.0 million of stock already sold under the existing March 11, 2024 agreement, provides Cadrenal with flexible, discretionary access to incremental capital, while specifying parameters such as trading periods, volume limits, and minimum prices, and compensating H.C. Wainwright with a 3% fee on gross sales, with no obligation for the company to sell any shares and the ability for either party to terminate the arrangement under agreed conditions.

The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.

Cadrenal Therapeutics Announces New Securities Purchase Agreement

On December 15, 2025, Cadrenal Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 207,374 shares of common stock and unregistered warrants to purchase up to 414,748 shares, aiming to raise approximately $2.2 million. The offering, expected to close on December 16, 2025, includes a lock-up period and restrictions on further stock issuance, impacting the company’s financial strategy and market operations.

The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.

Cadrenal Therapeutics Acquires VLX-1005 from Veralox

On December 10, 2025, Cadrenal Therapeutics acquired VLX-1005 and related assets from Veralox Therapeutics, enhancing its pipeline with a first-in-class drug candidate targeting immune signaling pathways in HIT. This acquisition, announced on December 11, 2025, positions Cadrenal to address the $40 billion global anticoagulation market and the $1 billion HIT market in the US and EU. VLX-1005, which has received Orphan Drug and Fast Track designations from the FDA, has shown promising results in Phase 1 and Phase 2 studies, potentially improving patient outcomes. The acquisition agreement includes upfront and milestone payments to Veralox, along with royalties on future global sales, enabling Cadrenal to focus on advancing VLX-1005’s clinical development.

The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.

Cadrenal Therapeutics Appoints Dr. Golden to Board

On December 1, 2025, Cadrenal Therapeutics announced the appointment of Dr. Lee Scott Golden to its Board of Directors. Dr. Golden brings over 25 years of experience in clinical development, particularly in cardiovascular medicine and anticoagulation, aligning with the company’s mission to advance safer anticoagulant options. His expertise is expected to guide Cadrenal’s strategy and clinical programs, potentially enhancing its industry positioning and value for shareholders.

The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.

Cadrenal Therapeutics Announces New Stock Offering Program

On November 18, 2025, Cadrenal Therapeutics, Inc. announced the filing of a prospectus supplement with the SEC for an ‘at the market offering’ program, allowing the sale of up to $3,438,062 of its common stock through H.C. Wainwright & Co., LLC. This move follows the company’s previous sale of $9,386,964 in shares under the same agreement. The offering is conducted under a registration statement effective since March 2024, and the agreement allows for flexible sales parameters. The company retains the right to suspend or terminate the agreement, and Wainwright will receive a 3% commission on sales.

The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.